Share This Page

New Weekly Alzheimer’s Injection Brings Care Home

Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
Leqembi IQLIK Autoinjector

If you’re supporting a loved one with early-stage Alzheimer’s, you understand how demanding treatment can be—especially biweekly hour‑long infusions at a clinic. The good news? As of August 29, 2025, the FDA has approved an at‑home, once‑weekly under‑the‑skin injection—Leqembi IQLIK—for those transitioning from initial intravenous (IV) therapy.


Benefits of the New Subcutaneous Option

  • Convenience: Takes just 15 seconds to administer at home via an autoinjector—no infusion center visits required
  • Flexible care: After 18 months of IV treatment, patients may either:
    1. Continue with monthly IV infusions, or
    2. Switch to weekly at‑home injections.
  • Better tolerability: Less than 1% of patients on the subcutaneous version experienced systemic reactions—versus around 26% on IV.
  • Maintained benefit: Clinical and biomarker benefits remain comparable to continued IV dosing when switching to weekly subcutaneous injections.
  • Accessible launch: Set to be available in the U.S. starting October 6, 2025.
  • Patient impact: Reduces travel time, lessens stress and risk for those in rural areas or with mobility issues.

Safety Profile & Clinical Context

  • Based on solid data: Approval relied on sub-studies from the Phase 3 Clarity AD open-label extension trial, involving over 600 patients, including 49 who received the 360 mg weekly injection.
  • No injection-related adverse events reported in those patients.
  • ARIA risks remain: Rates of amyloid-related imaging abnormalities are similar to the IV version and mostly occur early in therapy .
  • Clinical benefit continues: Data from Clarity AD show ongoing cognitive benefit, including slowed decline on scales like the CDR‑Sum of Boxes over 48 months.

What This Means for You

  • Ease of care: No more travel or tedious clinic visits—treatment becomes more manageable for both patients and caregivers.
  • Real-world adoption: Home injections could improve treatment adherence and quality of life, enabling more people to stay on therapy longer.
  • Looking ahead: Eisai and Biogen plan to seek approval for starting treatment with the subcutaneous form—potentially simplifying the process even further.

Actionable Takeaways

  1. Ask your neurologist or care team whether transitioning to the weekly autoinjector is right for your situation.
  2. Stay up to date—the first doses are expected to be available in the U.S. by October 6, 2025.
  3. Remain vigilant for ARIA or other safety issues, especially during the early transition phase and maintain recommended monitoring.

Closing

This FDA approval marks a hopeful step toward more patient-centered Alzheimer’s care—offering flexibility, safety, and a lighter emotional and logistical load. If you’d like help explaining this option to others or want to explore writing on next-generation subcutaneous therapies, let me know—happy to help.

REFERENCES:

  FDA approval details via press release and news coverage 

  Clinical trial data and safety profiles from the Clarity AD studies: 

Related:

Email me when people comment
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

Caring for dementias such as Alzheimer's among family and friends, Peter committed to help preserve the dignity of people affected by Alzheimer's. AlzheimersWeekly.com is the fruit of that commitment.

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Dementia Books & Videos on Amazon:

More From Alzheimer's Weekly

Mother supporting grandmother with dementia, on wooden park bench, browsing mobile phone
Diagnosis

Differences in Lewy Body Dementia

EXCELLENT GUIDE ON LEWY BODY DEMENTIA (LBD). Commonly misdiagnosed as Alzheimer’s or Parkinson’s, you can prevent devastating results by learning how to spot key differences.

Read More »
Cleveland, Ohio
Diet

Alzheimer’s: It Matters Where You Live

VIDEO: 85 in Ikaria? Smile. On this Greek island, Alzheimer’s is almost non-existent. 85 in America? Your odds hit 50-50. Is it genes, diet or air? NBC travels to an unlikely place for answers: Cleveland, Ohio.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

Free:
Alzheimer's & Dementia
Weekly Newsletter

INCLUDES BONUS BOOKLET:
15 Simple Things You Can Do to Care For a Loved One with Dementia or Memory Loss
News, Treatments, Care Tips, Diet, Research, Diagnosis, Therapies & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter

0
Would love your thoughts, please comment.x
()
x